Urology Today.net

Site updated at Thursday, 12 May 2016

Common Urological Problems

Castration Resistant Prostate Cancer

PSA Drop Seen with New Prostate Cancer Drug

Half of a group of men with castration-resistant prostate cancer (CRPC) had biochemical responses to treatment with an investigational androgen receptor modulator, data from a preliminary clinical study showed.

During 12 weeks of treatment with galeterone, prostate-specific antigen (PSA) declined by at least 30% in 24 of 49 patients, 11 of whom had declines… PSA Drop Seen with New Prostate Cancer Drug   



Antifungal May Help in Prostate Cancer

Men with castration-resistant prostate cancer (CRPC) that was not mediated by androgen suppression experienced better outcomes when treated with an antifungal agent, according to a small clinical study reported here.

Men treated with the maximum recommended dose of itraconazole had a median progression-free survival (PFS) of 36 weeks, and 61% of the patients were… Antifungal May Help in Prostate Cancer   



Zytiga Prednisone Combo Metastatic Castration-Resistant Prostate Cancer Trial Unblinded

A new statement by Janssen Research & Development, LLC informs that they have unblinded the Phase 3 study, COU-AA-302, which shows that Zytiga (abiraterone acetate), when taken alongside prednisone, is effective in treating mildly symptomatic or asymptomatic patients who are suffering from metastatic castration-resistant prostate cancer (CRPC) and have not gone through chemotherapy. … Zytiga Prednisone Combo Metastatic Castration-Resistant Prostate Cancer Trial Unblinded   



For advanced prostate cancer, new drug slows disease

A new medication proved effective in slowing the spread of metastatic prostate cancer, while helping to maintain the quality of life, in patients with advanced disease. The phase 3 study was unblinded midway, allowing patients receiving the placebo to instead take the drug because of the favorable results.

The study is the first randomized… For advanced prostate cancer, new drug slows disease   



FDA Approves Xtandi for Late-Stage Castration-Resistant Prostate Cancer

The U.S. Food and Drug Administration today approved Xtandi (enzalutamide) to treat men with late-stage (metastatic) castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone.

Approved for prostate cancer patients previously treated with docetaxel, another anti-cancer treatment, Xtandi was reviewed under the FDA’s priority review program.… FDA Approves Xtandi for Late-Stage Castration-Resistant Prostate Cancer   



fluid intake1 - urinary albumin-to-creatinine ratio1 - tgen1 - melamine-induced kidney disease1 - urinary complaints1 - primary hematuria1 - conners parent rating scale-revised1 - psa21 - pet1 - psa test10 - attention deficit hyperactivity disorder1 - diarrhea1 - glomerulopathy1 - cancer2 - ontario health insurance plan1 - the journal of urology2 - mild hypertension1 - peritoneal dialysis3 - trabecular bone1 - proscar1 - invasive technique1 - high triglycerides1 - adolescent obesity1 - prostate cancer imaging1 - prostate cancer drug2 - implantable contraception1 - proteinuria8 - sex2 - nephrons2 - dehydration1 -